| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |
|
Medicine details |
|
| Medicine name | abrocitinib (Cibinqo®) |
| Formulation | 50 mg, 100 mg, 200 mg film-coated tablet |
| Reference number | 3717 |
| Indication | Treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy |
| Company | Pfizer Ltd |
| BNF chapter | Skin |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/12/2021 |
| NICE guidance | TA814: Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis |